Search Medical Condition
Please enter condition
Please choose location

Adverse Effects, Drugs Clinical Trials

A listing of Adverse Effects, Drugs medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (29) clinical trials

Post-market Safety Reassessment of Ulinastatin for Injection

In order to find out the application of ulinastatin in real practice clinic , identify the high risk group for adverse event/adverse drug reaction and calculate the adverse event/adverse drug reaction incidence rate, a large sample size clinical trial has been designed. This trial is an observational study. The investigators ...

Phase N/A

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

The majority of HIV-1 infected patients in resource rich countries receive the tenofovir prodrug tenofovir disoproxil fumarate (TDF) as part of their combination antiretroviral therapy (cART). Long-term exposure to TDF can be associated with an accelerated estimated glomerular filtration rate (eGFR) decline and proximal renal tubular dysfunction (PTD, see definition ...


National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals. ...

Phase N/A

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

The purpose of this study is to determine whether genomic effects on antidepressant response differed by class of drug, whether genomic differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically ...

Phase N/A

Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention

Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada ...

Phase N/A

FLUAD vs. Fluzone High-Dose Study

The overall aim of the study is to compare safety and immunogenicity of adjuvanted inactivated influenza vaccine (IIV) (FLUAD) versus High-Dose inactivated influenza (Fluzone High Dose) vaccine in 65 years (20% aged 80 years). A prospective, randomized, blinded clinical trial that will be conducted during the 2017/2018 and 2018/2019 influenza ...


High-Dose Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)


Patients are needed to participate in a clinical research study to evaluate overdose of drug with toxic effect, Drug-induced Disorder of Liver

Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could ...

Phase N/A

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

This study will help determine which types of drugs that may interact with Lu AF35700


Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation

In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the level of adherence will be measured using a questionnaire, the Danish National Prescription Registry and pillcount and will be related to plasma levels of dabigatran measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and coagulation assays. The aim of ...

Phase N/A